Tonix Pharmaceuticals Announces Medicare Part D Coverage for TONMYA

What Happened

• On September 22, 2026, Tonix Pharmaceuticals Holding Corp. announced it entered into an agreement with a pharmacy benefit manager (PBM), effective immediately, that provides Medicare Part D coverage for TONMYA® to approximately 21 million beneficiaries.
• The company further reported that, to date, government and commercial coverage for TONMYA is available to roughly 166 million individuals.

Key Details

• Filing date: September 22, 2026 (Current Report on Form 8-K).
• PBM agreement effective immediately; adds ~21 million Medicare Part D plan beneficiaries.
• Total reported government and commercial coverage for TONMYA: ~166 million individuals.
• The filing includes the company’s standard forward-looking statements caution about risks and uncertainties.

Why It Matters

• This filing documents expanded payer coverage for TONMYA, a factual increase in reported access that investors commonly track as part of assessing a drug’s commercial rollout and potential uptake.
• The added Medicare Part D coverage and the stated total coverage figure (≈166 million) are concrete, company-reported metrics that may influence future prescription access and revenue potential.
• The company also reminds readers of standard forward-looking statement risks and that actual results may differ from projections.